ALERT: Your health is top priority. We’re committed to providing reliable COVID-19 resources to keep you informed and safe.

Testosterone Replacement Therapy Lawsuits Tentatively Settled


Editors carefully fact-check all Drugwatch content for accuracy and quality.

Drugwatch has a stringent fact-checking process. It starts with our strict sourcing guidelines.

We only gather information from credible sources. This includes peer-reviewed medical journals, reputable media outlets, government reports, court records and interviews with qualified experts.

Judge in courtroom holding gavel

Allergan has tentatively agreed to settle more than 500 testosterone replacement therapy lawsuits. Men who filed the lawsuits blame the company’s drug Androderm for heart attacks, strokes, blood clots and sudden death.

U.S. District Judge Matthew F. Kennelly entered an order June 28. It disclosed the proposed settlement.

Kennelly is presiding over multidistrict litigation (MDL) involving testosterone replacement therapy drugs. He put all the pending Androderm cases on hold while the details are worked out.

The Androderm cases actually name Actavis as the defendant. Allergan took over Actavis in 2014.

Allergan’s most recent quarterly report filed with the Securities and Exchange Commission said there were about 525 pending actions involving Androderm in the testosterone MDL.

Allergan joins Eli Lilly and Co. and Endo’s Auxilium Pharmaceuticals in tentatively settling their testosterone replacement therapy cases in the MDL.

Eli Lilly faces about 400 lawsuits involving the drug Axiron. Endo faces about 1,300 lawsuits involving Testim.

Another company, AbbVie, still faces about 4,300 lawsuits in the MDL over its testosterone replacement drug, AndroGel.

Some AndroGel trials ended in multimillion-dollar verdicts for patients who claimed testosterone therapy side effects. Others ended in victories for AbbVie.

Last week, a court ordered AbbVie and Partner Besins Healthcare Inc. to pay $448 million to consumers who were overcharged for AndroGel. The award is the largest ever in a litigated Federal Trade Commission antitrust case.

The FTC had sued AbbVie in 2014. The federal government accused AbbVie of illegally blocking consumers’ access to lower-cost versions of AndroGel. The FTC said AbbVie filed baseless patent infringement lawsuits against potential generic competitors.

A federal judge in Pennsylvania sided with the FTC.

“This decision is a double victory, both for patients who rely on Androgel and for competition more broadly,” said FTC Chairman Joe Simons in a statement. “It sends a clear signal that pharmaceutical companies can’t use baseless litigation to forestall competition from low-cost generics.”

AbbVie says it plans to appeal the judgment.

“We are disappointed by the ruling. We believe our conduct was lawful and the damages award is improper. We intend to appeal,” said an AbbVie spokeswoman, Toni Haubert, in a statement to MarketWatch.

Elaine Silvestrini
Written By Elaine Silvestrini Writer

Elaine Silvestrini is an award-winning journalist with 30 years of experience covering state and federal court systems. She joined Drugwatch in 2017. Her coverage for Drugwatch has been cited in the CDC’s Public Health Law News and the USA Today Network. Some of her qualifications include:

  • Centers for Disease Control and Prevention certificates in Health Literacy
  • Experience as an assistant investigator for the Federal Public Defender
  • Loyola Law School Journalist Law School Fellowship
Edited By
Emily Miller
Emily Miller Managing Editor

8 Cited Research Articles writers follow rigorous sourcing guidelines and cite only trustworthy sources of information, including peer-reviewed journals, court records, academic organizations, highly regarded nonprofit organizations, government reports and interviews with qualified experts. Review our editorial policy to learn more about our process for producing accurate, current and balanced content.

  1. Federal Trade Commission. (2018, June 29). Statement of FTC Chairman Joe Simons Regarding Federal Court Ruling in FTC v. AbbVie. Retrieved from
  2. Federal Trade Commission. (2014, September 8). FTC Sues Pharmaceutical Companies for Illegally Blocking Consumer Access to Lower-Cost Versions of Blockbuster Drug AndroGel. Retrieved from
  3. United States District Court Northern District of Illinois Eastern Division. (2018, June 29). In Re Testosterone Replacement Therapy Products Liability Litigation. Case 1:14 cv 1748. Documents 2767. Case Management Order No. 128 (Stay of Cases Involving Claims Against Actavis Defendants). Retrieved from
  4. Allergan. (2014, November 17). Actavis to Acquire Allergan to Create Top 10 Global Growth Pharmaceutical Company with $23 Billion in Revenue. Retrieved from
  5. United States Securities and Exchange Commission. (2018, April 27). AbbVie Form 10-Q. Retrieved from
  6. United States Securities and Exchange Commission. (2018, May 3). Allergan Form 10-Q. Retrieved from
  7. Cherney, M.A. (2018, June 30). AbbVie says it will appeal $448 million antitrust judgment. Retrieved from
View All Sources
Who Am I Calling?

Calling this number connects you with one of Drugwatch's trusted legal partners. A law firm representative will review your case for free.

Drugwatch's trusted legal partners support the organization’s mission to keep people safe from dangerous drugs and medical devices. For more information, visit our partners page.

(888) 645-1617